ClinicalTrials.gg
RecruitingNCT07601737Updated Jul 9, 2026

Nimotuzumab Combined With Immunotherapy and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

A Phase 2 interventional study of Nimotuzumab Injection and Tislelizumab in Head and Neck Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC) and Head & Neck Cancer, sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-07-09.

Sponsored by Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine · Phase 2, Interventional, and Treatment

How we know · 6 judgments

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
182
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck — 6 open to participants now, 6 under way, 2 of them phase 3. nimotuzumab · Squamous Cell Carcinoma of Head and Neck.

Planned enrollment
4th of 12
182 · median 93
Started
2026
with 3 others
Phase 2
8 of 12
3 open now
Registered
12th of 12
by date
Lead sponsor
1 of 12
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

Among the 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck, this one is the 4th largest by planned enrollment, is one of 4 that started in 2026, is one of 8 in phase 2, and was the 12th registered.

Squamous Cell Carcinoma of Head and Neck

2,023 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

6 of the 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About nimotuzumab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 434 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 310 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies testing nimotuzumab in Squamous Cell Carcinoma of Head and Neck, or all of them as a file.
02

Study summary

This is a randomized controlled, phase II clinical study designed to explore the efficacy and safety of nimotuzumab combined with immunotherapy and chemotherapy as neoadjuvant treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). The primary endpoint of the study is the 2-year event-free survival (EFS) rate. Enrollment is expected to be completed within 2 years; all patients will be followed up for at least 2 years after the last patient is enrolled.

03

Conditions studied

  • Head and Neck Squamous Cell Carcinoma
  • Head and Neck Squamous Cell Carcinoma (HNSCC)
  • Head & Neck Cancer
  • Neoadjuvant Therapy
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 to 75 years inclusive.
  2. or cytologically confirmed squamous cell carcinoma of the head and neck (HNSCC) (oral cavity, oropharynx, larynx, hypopharynx), stage III-IVB per AJCC 8th edition.
  3. Resectable disease assessed by a multidisciplinary team (MDT) including surgical, radiological, and pathological specialists.
  4. (ECOG) performance status 0 or 1.
  5. For oropharyngeal carcinoma: mandatory p16 immunohistochemistry (testing within standard of care is acceptable; repeat testing not required). p16 testing is not required for other tumor locations.
  6. Availability of tumor tissue (archived or newly obtained) for testing (prior testing is acceptable; repeat testing not required).
  7. At least one per 1.1.
  8. ≥ 6 months.
  9. Adequate hematologic function:

    White blood cell count ≥ 4.0 × 10⁹/L ≥ 1.5 × 10⁹/L count ≥ 100 × 10⁹/L ≥ 90 g/L

  10. Adequate renal function:

    Serum creatinine ≤ 1.5 × (ULN) OR

    (CrCl) ≥ 60 mL/min calculated by Cockcroft-Gault formula:

    Female: CrCl (mL/min) = (140 - age) × body weight (kg) × 0.85 / (72 × serum creatinine (mg/dL)) Male: CrCl (mL/min) = (140 - age) × body weight (kg) × 1.00 / (72 × serum creatinine (mg/dL))

  11. Adequate hepatic function:

    Total ≤ 1.5 × ULN (AST) ≤ 2.5 × ULN Alanine aminotransferase (ALT) ≤ 2.5 × ULN

  12. Female subjects: negative pregnancy test within 2 weeks before first study drug, non-lactating.

    Females: highly effective required during study and for 6 months after last study drug.

    Males: highly effective contraception required during study and for 6 months after last study drug.

  13. Written obtained prior to any study-specific procedures, and willingness to comply with all study visits and protocol requirements.

Exclusion criteria

Exclusion Criteria:

  1. Received inhibitors, EGFR monoclonal antibodies, EGFR-TKIs, or anti-angiogenic agents within 4 weeks prior to enrollment.
  2. Participation in another interventional clinical trial within 30 days prior to screening.
  3. In the investigator's judgment, the patient cannot tolerate or has to platinum-based chemotherapy (cisplatin or carboplatin) as specified in the protocol.
  4. Unresectable disease, poor medical condition for surgery, refusal of surgery for any reason, or excessive tumor burden precluding resection.
  5. History of other within the past 5 years (except cured basal cell carcinoma of the skin).
  6. History of primary immunodeficiency disease.
  7. Presence of uncontrolled comorbidities, including heart failure, severe pulmonary disease, severe hepatic disease, psychiatric disorders, etc.
  8. Known infection, active viral hepatitis, or active tuberculosis.
  9. Underwent major surgery within 90 days prior to the first study drug, or planning major surgery unrelated to this cancer treatment.
  10. to any study drug or their components.
  11. Pregnant (confirmed by serum or urine HCG test) or lactating woman; or subject of unwilling or unable to use effective during study treatment and for at least 6 months after the last dose of study treatment (applicable to both males and females).
  12. Investigator considers the subject not suitable for study participation.
  13. Unwilling to participate or unable to provide written .
  14. Receipt of a within 30 days before the first study drug administration.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
182 participants (estimated)

Study arms

  • Experimental
    Study Group

    1. Nimotuzumab ,Albumin-bound paclitaxel and cisplatin administration on days 3 and 24, tislelizumab (or pembrolizumab) administration on days 1 and 22; 2. Standard of care surgery

    Drug: Nimotuzumab Injection · Drug: Tislelizumab · Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel · Drug: Cisplatin (Or Carboplatin) · Procedure: Radical surgery of tumor · Radiation: Concurrent chemoradiotherapy

  • Active comparator
    Control Group

    1.Standard of care surgery

    Procedure: Radical surgery of tumor · Radiation: Concurrent chemoradiotherapy

Interventions

  • DrugNimotuzumabStudies of NimotuzumabNimotuzumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Nimotuzumab 400mg,d3,Q3W,for two cycles。

    Also known as: Nimotuzumab

  • tislelizumab (or pembrolizumab) 200mg,d1,Q3W,for two cycles。

    Also known as: pembrolizumab

  • DrugAlbumin-Bound Paclitaxel /nab-Paclitaxel

    Drug page: Albumin-Bound PaclitaxelStudies of Albumin-Bound PaclitaxelAlbumin-Bound Paclitaxel pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Albumin-bound paclitaxel 180 mg/m² (or docetaxel 75 mg/m²), administered on day 3, every 3 weeks (Q3W);for two cycles。

    Also known as: docetaxel

  • DrugCisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cisplatin 75 mg/m² (carboplatin AUC=5 may be substituted if cisplatin is not tolerated), administered on day 3, every 3 weeks (Q3W).for two cycles。

    Also known as: Cisplatin, carboplatin

  • ProcedureRadical surgery of tumor

    Standard radical surgery of tumor

  • RadiationConcurrent chemoradiotherapy

    Concurrent chemoradiotherapy: Radiotherapy: intensity modulated conformal radiotherapy (IMRT) was used with a total dose of 60-66gy (2gy/f, 30-33f). Chemotherapy: Cisplatin 40 mg/m2, QW, 6-7 times in total; Targeting: nimotuzumab 200mg, QW, 6-7 times in total.

This study also gives PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. 2-Year Event-Free Survival (EFS) Rate

    Time frame: From first study treatment up to 2 years after the last patient randomized.

Secondary outcomes

  1. Major Pathologic Response (MPR)

    Time frame: Within 4 weeks after surgery.

  2. Pathological Complete Response (pCR)

    Time frame: Within 4 weeks after surgery.

  3. Objective Response Rate (ORR)

    Time frame: After 2 cycles (each cycle is 21 days) of neoadjuvant treatment.

  4. 2-Year Overall Survival (OS) Rate

    Time frame: From first study treatment up to 2 years after the last patient randomized.

  5. Quality of Life (QoL)

    Assessed using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires QLQ-C30 (V3.0). EORTC QLQ-C30 V3.0:The scale consists of general domain items and global health and quality of life items. General domain items are further divided into functional domains and symptom domains. The raw scores of general items range from 1 (minimum) to 4 (maximum), while those of global health and quality of life items range from 1 (minimum) to 7 (maximum). All raw scores are finally standardized to scores ranging from 0 to 100. In functional domains including PF, RF, EF, CF, SF and QL, higher scores indicate better functional status. In symptom domains including FA, NV, PA, DY, SL, AP, CO, DI and FI, higher scores stand for more severe symptoms. For the global health and quality of life domain, higher scores reflect better general health condition and quality of life.

    Time frame: Baseline(Screening) After neoadjuvant chemotherapy:Study Group(S)Week6 /Control Group(C)NA Post-surgery:S Week 9/C Week 3 After adjuvant radiotherapy(S Week 21/C Week 15) End of treatment(Week 24) Follow-up: Month 6, Month 12, Month 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Apr 2028, 24 months after the start.

Of 299 non-industry phase 2 interventional studies under Squamous Cell Carcinoma of Head and Neck, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 85. This study's planned 24 months is below that.

Counting every sponsor, half of 366 studies reached it within 53 months; a quarter within 35 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2026
First posted
May 22, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Apr 30, 2028
CompletionEst.
Apr 30, 2030
Last update
Jul 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07601737
Responsible party
Pin Dong (Professor, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine) — Principal investigator
First posted
May 22, 2026
Start date
Apr 20, 2026
Primary completion
Apr 30, 2028 (estimated)
Completion
Apr 30, 2030 (estimated)
Last update
Jul 9, 2026

Study contacts

xin wei chen
Contact
xinwei.chen@shgh.com
86+18616017916

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nimotuzumab

Start the discussion